The Precision Medicine Economy

You hired smart people. You trust your staff. Your NPs and PAs are sharp. Your office manager keeps the trains running.

None of that matters when the board comes calling.

If your practice is offering peptide therapies, there is one thing you need to understand before anything else. Your name is on every script. Your license is on every protocol. Your liability is on every patient outcome. Not your injector's. Not your sales rep's. Not the clinic down the street that told you "everyone is doing it."

Yours.

And right now, most medical directors walking into this space have no idea how exposed they are.

Here is what I see every week across practices in dozens of states.

Front desk staff making therapeutic claims on the phone they are not qualified to make. Social media posts from your clinic promising outcomes that no IRB-reviewed study supports. Providers ordering compounds from sources that cannot produce a certificate of analysis on demand. Staff recommending peptide protocols they learned from a weekend seminar or an Instagram influencer with a supplement line.

Every one of those moments is a liability event with your name attached.

You do not need to be in the room. You do not need to have approved the post. You do not need to have signed off on that conversation. You are the medical director. The regulatory assumption is that you knew, or should have known.

That is not a gray area. That is how enforcement works.

Peptide therapies have real clinical utility. That is not the debate. BPC-157, PT-141, thymosin alpha-1, CJC/ipamorelin. There is legitimate literature supporting investigation and clinical use in appropriate patient populations.

But legitimate and unregulated are not the same thing.

If your practice is sourcing peptides, here is the baseline you need to meet before you prescribe a single dose.

Your pharmacy must be a licensed 503A compounder. Not a research chemical supplier. Not an overseas manufacturer. Not a company that ships vials in unmarked packaging with no prescriber relationship. A state-licensed, FDA-registered 503A sterile compounding pharmacy with lot-level traceability, beyond-use dating, and potency verification.

You need to know what left the FDA's shortage list and what didn't. The regulatory landscape shifted hard when tirzepatide came off the FDA shortage list. Semaglutide is under similar scrutiny. If your compound pharmacy is still filling these without understanding the current legal standing, you are exposed. If you are prescribing them without understanding the current legal standing, you are more exposed.

Your protocols need documented clinical rationale. Not "the patient asked for it." Not "the rep said it was safe." You need documented indications, dosing frameworks grounded in available evidence, and informed consent that actually informs. If your consent form is a paragraph your office manager pulled from a template site, it is not protecting you.

This is not a five-year plan. This is a Monday morning checklist.

Audit your sourcing. Call your compound pharmacy. Ask for their state licenses, FDA registration, and a certificate of analysis for the last peptide lot they shipped you. If they hesitate, find a new pharmacy.

Audit your team's language. Pull your clinic's social media. Read your front desk scripts. Listen to how your staff describes peptide therapies to patients. If you hear the word "cure" or "miracle" or "FDA-approved" in the context of any compounded medication, shut it down that day.

Audit your consent forms. If your informed consent does not clearly state that compounded medications are not FDA-approved finished drugs, it is incomplete. If your patients are signing forms that do not outline the specific risks, alternatives, and limitations of compounded peptide therapy, you are not informed consenting. You are collecting signatures.

Get your protocols in writing. Every peptide your practice prescribes should have a documented protocol with clinical rationale, dosing parameters, contraindications, and monitoring requirements. If it lives in someone's head instead of in a binder, it is not a protocol. It is a guess.

Know your pharmacy's compliance posture. Ask your compounding pharmacy how they handle a recall. Ask them what happens when a state board audits their records. Ask them if they can produce batch-level documentation for every vial they have ever shipped to your practice. If they cannot answer those questions without hesitation, they are not a partner. They are a risk.

The peptide space is full of clinical promise. It is also full of people who will let you take the regulatory hit while they collect the margin.

Your staff is not trying to put you at risk. But they will if you do not set the guardrails. Your vendors are not trying to compromise your license. But they will if you do not ask the hard questions.

You are the medical director. The clinical buck stops with you. The regulatory buck stops with you. The patient safety buck stops with you.

Build the infrastructure before you build the revenue. Know what you are prescribing, where it comes from, who is saying what about it, and whether any of it can survive a board review.

If it cannot, do not do it. No therapy is worth your license. No margin is worth a patient outcome you cannot defend.

Your name is on the door. Act like it.

I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.

This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.

If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.